Finance

Lists
INVA:NASDAQ
Innoviva Inc
$21.08
+1.44%
(+0.30) 1D
$21.08
0.00% (0.00)
After hours
Closed: Oct 19, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for INVA...
Open
$20.68
High
$21.15
Low
$20.68
Mkt. cap
1.52B
Avg. vol.
922.12K
Volume
590.32K
P/E ratio
5.08
52-wk high
$25.14
52-wk low
$17.13
EPS
$4.15
Beta
0.38
Shares outstanding
72.24M
No. of employees
159
Open
$20.68
High
$21.15
Low
$20.68
Mkt. cap
1.52B
Avg. vol.
922.12K
Volume
590.32K
P/E ratio
5.08
52-wk high
$25.14
52-wk low
$17.13
EPS
$4.15
Beta
0.38
Shares outstanding
72.24M
No. of employees
159
News stories
From web sources and news partners
About Innoviva Inc
CEO-
Employees159
Founded1996
HeadquartersSouth San Francisco, California, United States
SectorPharmaceutical industry
Websiteinva.com
Analyst ratings
Based on 4 analysts giving stock ratings to INVA in the past 3 months
Strong buy
Buy
4
Hold
0
Sell
0
12-month forecast
Based on 4 Wall Street analysts offering 12 month price targets for INVA in the last 3 months.
Highest
Current $21.08
$46.00 (+118.22%)
Average
$39.25 (+86.20%)
Lowest
$34.00 (+61.29%)
Analyst
Recommendation
Action
Price target
Projected
Date
Les Sulewski
Oppenheimer
Buy
Initiated
$35.00
+66%
09/23/2026
Unknown Analyst
Oppenheimer
Buy
Initiated
$35.00
+66%
09/23/2026
Steven Seedhouse
Cantor Fitzgerald
Buy
Maintained
$34.00
+61.3%
08/20/2026
Ram Selvaraju
H.C. Wainwright
Buy
Reiterated
$46.00
+118.2%
08/10/2026
Julian Harrison
BTIG
Buy
Maintained
$42.00
+99.2%
08/05/2026
Asad Haider
Goldman Sachs
Sell
Maintained
$18.00
-14.6%
05/06/2026
Trevor Allred
Oppenheimer
Buy
Downgraded
$35.00
+66%
02/26/2026
Last report
Aug 5, 2026
Fiscal period
Q2 2026
$0.56 / $0.50
+11.46%beat
Revenue / Est. (USD)
119.59M / 110.68M
+8.05%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
107.80M
114.61M
97.99M
119.59M
Cost of goods sold
35.69M
36.18M
14.46M
21.45M
Cost of revenue
35.69M
36.18M
14.46M
21.45M
Research and development expenses
-
-
5.24M
5.19M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
27.41M
32.08M
32.44M
34.57M
Operating expense
34.03M
38.71M
44.23M
46.39M
Total operating expenses
69.72M
74.89M
58.69M
67.84M
Operating income
38.08M
39.72M
39.30M
51.76M
Other non operating income
-479.00K
-612.00K
-366.00K
-15.00K
EBT including unusual items
97.82M
195.04M
234.56M
-108.02M
EBT excluding unusual items
39.06M
41.95M
44.49M
53.87M
Income tax expense
7.91M
30.88M
47.97M
-24.60M
Effective tax rate
8.09%
15.83%
20.45%
22.77%
Other operating expenses
-
-
-
-
Net income
89.91M
164.15M
186.60M
-83.42M
Net profit margin
83.40%
143.22%
190.41%
-69.75%
Earnings per share
0.38
0.47
0.47
0.56
Interest and investment income
5.47M
6.15M
10.99M
7.60M
Interest expense
-4.02M
-3.31M
-5.44M
-5.47M
Net interest expenses
1.46M
2.84M
5.55M
2.13M
Depreciation and amortization charges
-
-
-
-
EBITDA
44.73M
46.39M
45.89M
58.45M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps